AstraZeneca signs agreement with Sanofi’ Genzyme to divest Caprelsa

27 Jul 2015 Evaluate

AstraZeneca the parent company of AstraZeneca Pharma has signed an agreement with a unit of French pharmaceutical company Sanofi for the sale of cancer drug Caprelsa for $300 million. The company entered into a definitive pact with Genzyme to divest Caprelsa, which is used for treating thyroid cancer. The medicine is currently available in 28 countries and had sales of $48 million in 2014.

Under the agreement, Sanofi’s rare diseases unit Genzyme will pay AstraZeneca an upfront payment of $165 million to acquire the global rights to sell and develop Caprelsa, and further development and sales milestone payments of up to $135 million. The transaction doesn't include the transfer of any AstraZeneca employees or facilities. The sale is expected to complete in the second half of 2015 and doesn't affect AstraZeneca's 2015 earnings guidance.

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases.

Astrazeneca Pharma I Share Price

8728.45 -233.50 (-2.61%)
25-Apr-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1786.85
Dr. Reddys Lab 1173.55
Cipla 1525.50
Lupin 2018.35
Zydus Lifesciences 859.10
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
×
Please wait your portfolio is updating...